

## Oculus Innovative Sciences to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference

Presentation and Live Webcast on Tuesday, February 19, 2008, at 1:30 p.m. PST

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), today announced that Hoji Alimi, the Company's CEO and founder, will present a corporate overview and clinical update at the Roth Capital Partners 20th Annual OC Growth Stock Conference to be held at the Ritz Carlton in Laguna Niguel, California. Mr. Alimi's presentation is scheduled on Tuesday, February 19, 2008, at 1:30 p.m. PST, in the Promenade, with a breakout session to immediately follow.

The presentation will be broadcast live and replayed for 90 days on Oculus Innovative Sciences' website at <a href="http://ir.oculusis.com/events.cfm">http://ir.oculusis.com/events.cfm</a>. To listen to the live broadcast, please visit the website at least 15 minutes early to register and download any necessary audio software.

Participation in the conference is by invitation only. For more information on the conference, please contact your Roth representative or visit <a href="https://www.rothcp.com">www.rothcp.com</a>.

## **About Oculus**

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible solution containing active oxychlorine compounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The technology has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. It has been commercialized outside of the United States for the treatment of infected wounds. Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V., and Oculus Japan K.K. Oculus' website is <a href="https://www.oculusis.com">www.oculusis.com</a>.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective

owners.

Source: Oculus Innovative Sciences, Inc.